{"ticker": {"uuid": "dc23b6c1-ab7d-41ce-b9cb-67e0d1817984", "symbol": "4594", "name": "BrightPath Biotherapeutics Co., Ltd.", "exchange": "JPX", "country": "JP", "sector": "Healthcare", "industry": "Biotechnology"}, "articles": [{"title": "Enterprise value to revenue forward of BrightPath Biotherapeutics Co.Ltd. \u2013 TSE:4594", "summary": "", "url": "https://news.google.com/rss/articles/CBMiqAFBVV95cUxQQlc2WU5aV081Z29pWElxejBpWllSQmZIazYzLXIzUG9YYzVMRXZ1bmhkOWN6Q2FFUHNrckV6amF6Q2UxbGVBbm5FQ2VKQ1JYanR1SjhZVEticGRuR3FRVTVZTkJ0YXFoU1FmQUxHaVFfeXVmSGo2bkFhcXhyeDNWSngyeVpsTUFiV3dLelVtQjhWMTRya05JWkh1TkhUWjlrX0VGcFhfMHc?oc=5", "source_name": "TradingView", "published_at": "2026-07-09T12:43:13+00:00", "published_display": "09 Jul 2026 12:43", "sentiment": "neutral", "sentiment_pct": 50, "event_type": "earnings", "event_label": "Earnings", "event_confidence": 53, "tier": "direct", "tier_label": "Direct company coverage"}, {"title": "BrightPath Advances BP2202 Into Phase I for Tough-to-Treat Multiple Myeloma", "summary": "", "url": "https://news.google.com/rss/articles/CBMixgFBVV95cUxNMm5PcDRnMUhxc0tvVEhtOEVyRGxEUy1XUnZabnpvSEl6cl8xVW9RN3dZQVYzQ2dwVWtzZXJHOElCWU1uZ2g4TTZuRmNoSjNrZnJzNVBJRDJqcTVRN18ydzNlWkJPR2lYdUwyRHJTdW9lV1FONVhjZzkxd3U1M3l6bGRPclhxUFpYRC1uM3BHLXFRUEo1dlAtZHppU2N4eS05S3VNVTU3aVVoeVVMMk9TR0VNWGN4U20yVk44dVVrMmJ5Vko1RkE?oc=5", "source_name": "TipRanks", "published_at": "2026-07-01T07:00:00+00:00", "published_display": "01 Jul 2026 07:00", "sentiment": "neutral", "sentiment_pct": 50, "event_type": "general", "event_label": "Market update", "event_confidence": 35, "tier": "direct", "tier_label": "Direct company coverage"}, {"title": "Press Release Service: BrightPath Bio and Cellistic Announces Process Development and Manufacturing Collaboration for Phase 1 Clinical Trial of iPSC-derived BCMA CAR-iNKT cell", "summary": "", "url": "https://news.google.com/rss/articles/CBMi8AFBVV95cUxQc2lRcUNZTjFKOTlEb2V5WVhWT1lmeW5FSTF3dEdCZXpOWkxhSDNPb1dKamJsTG53cnFsWjhrNzkwUGJXZmEyWnoxQ2ZJVllCdkdBaDgwZXcwQU41Z1c4Wm9HYWRNMElkUGdkMVF3Yk5vTU9ZYnBpVGlpYmFXRDJnQjVxOE5HNDZVT0xnUnFST1ZUZ0RfQmpiZmtfS2E3SUR6UjBmYVBPT09QSEJVaTQzYjVwMGRwQ2daSERaaUkzaXIyOEQta1FILXJ3dnN4SDN0QmZmeFFtaDQ5Qmh4R0k2aUVPV2FBSjZUNkE4a2psVGU?oc=5", "source_name": "CRISPR Medicine News", "published_at": "2024-12-13T08:00:00+00:00", "published_display": "13 Dec 2024 08:00", "sentiment": "neutral", "sentiment_pct": 50, "event_type": "general", "event_label": "Market update", "event_confidence": 35, "tier": "direct", "tier_label": "Direct company coverage"}, {"title": "Technical Analysis of BrightPath Biotherapeutics Co.Ltd. (TSE:4594)", "summary": "", "url": "https://news.google.com/rss/articles/CBMiZ0FVX3lxTE9Bemp2dThBV2Q4eFJfaE5YSjBqOEQzN3dQOUd1M1pnc1owM2ZuY1lWSnN5RUlyUUllc1dCR1I4Y1dpdmEyU2pJRDAzQlZ5dTJlZjY5WEdEQUlvSEMzOW9BMGNlYVZ5SkE?oc=5", "source_name": "TradingView", "published_at": "2018-03-01T09:06:48+00:00", "published_display": "01 Mar 2018 09:06", "sentiment": "neutral", "sentiment_pct": 50, "event_type": "general", "event_label": "Market update", "event_confidence": 35, "tier": "direct", "tier_label": "Direct company coverage"}], "by_tier": {"direct": [{"title": "Enterprise value to revenue forward of BrightPath Biotherapeutics Co.Ltd. \u2013 TSE:4594", "summary": "", "url": "https://news.google.com/rss/articles/CBMiqAFBVV95cUxQQlc2WU5aV081Z29pWElxejBpWllSQmZIazYzLXIzUG9YYzVMRXZ1bmhkOWN6Q2FFUHNrckV6amF6Q2UxbGVBbm5FQ2VKQ1JYanR1SjhZVEticGRuR3FRVTVZTkJ0YXFoU1FmQUxHaVFfeXVmSGo2bkFhcXhyeDNWSngyeVpsTUFiV3dLelVtQjhWMTRya05JWkh1TkhUWjlrX0VGcFhfMHc?oc=5", "source_name": "TradingView", "published_at": "2026-07-09T12:43:13+00:00", "published_display": "09 Jul 2026 12:43", "sentiment": "neutral", "sentiment_pct": 50, "event_type": "earnings", "event_label": "Earnings", "event_confidence": 53, "tier": "direct", "tier_label": "Direct company coverage"}, {"title": "BrightPath Advances BP2202 Into Phase I for Tough-to-Treat Multiple Myeloma", "summary": "", "url": "https://news.google.com/rss/articles/CBMixgFBVV95cUxNMm5PcDRnMUhxc0tvVEhtOEVyRGxEUy1XUnZabnpvSEl6cl8xVW9RN3dZQVYzQ2dwVWtzZXJHOElCWU1uZ2g4TTZuRmNoSjNrZnJzNVBJRDJqcTVRN18ydzNlWkJPR2lYdUwyRHJTdW9lV1FONVhjZzkxd3U1M3l6bGRPclhxUFpYRC1uM3BHLXFRUEo1dlAtZHppU2N4eS05S3VNVTU3aVVoeVVMMk9TR0VNWGN4U20yVk44dVVrMmJ5Vko1RkE?oc=5", "source_name": "TipRanks", "published_at": "2026-07-01T07:00:00+00:00", "published_display": "01 Jul 2026 07:00", "sentiment": "neutral", "sentiment_pct": 50, "event_type": "general", "event_label": "Market update", "event_confidence": 35, "tier": "direct", "tier_label": "Direct company coverage"}, {"title": "Press Release Service: BrightPath Bio and Cellistic Announces Process Development and Manufacturing Collaboration for Phase 1 Clinical Trial of iPSC-derived BCMA CAR-iNKT cell", "summary": "", "url": "https://news.google.com/rss/articles/CBMi8AFBVV95cUxQc2lRcUNZTjFKOTlEb2V5WVhWT1lmeW5FSTF3dEdCZXpOWkxhSDNPb1dKamJsTG53cnFsWjhrNzkwUGJXZmEyWnoxQ2ZJVllCdkdBaDgwZXcwQU41Z1c4Wm9HYWRNMElkUGdkMVF3Yk5vTU9ZYnBpVGlpYmFXRDJnQjVxOE5HNDZVT0xnUnFST1ZUZ0RfQmpiZmtfS2E3SUR6UjBmYVBPT09QSEJVaTQzYjVwMGRwQ2daSERaaUkzaXIyOEQta1FILXJ3dnN4SDN0QmZmeFFtaDQ5Qmh4R0k2aUVPV2FBSjZUNkE4a2psVGU?oc=5", "source_name": "CRISPR Medicine News", "published_at": "2024-12-13T08:00:00+00:00", "published_display": "13 Dec 2024 08:00", "sentiment": "neutral", "sentiment_pct": 50, "event_type": "general", "event_label": "Market update", "event_confidence": 35, "tier": "direct", "tier_label": "Direct company coverage"}, {"title": "Technical Analysis of BrightPath Biotherapeutics Co.Ltd. (TSE:4594)", "summary": "", "url": "https://news.google.com/rss/articles/CBMiZ0FVX3lxTE9Bemp2dThBV2Q4eFJfaE5YSjBqOEQzN3dQOUd1M1pnc1owM2ZuY1lWSnN5RUlyUUllc1dCR1I4Y1dpdmEyU2pJRDAzQlZ5dTJlZjY5WEdEQUlvSEMzOW9BMGNlYVZ5SkE?oc=5", "source_name": "TradingView", "published_at": "2018-03-01T09:06:48+00:00", "published_display": "01 Mar 2018 09:06", "sentiment": "neutral", "sentiment_pct": 50, "event_type": "general", "event_label": "Market update", "event_confidence": 35, "tier": "direct", "tier_label": "Direct company coverage"}], "industry": [], "sector": []}, "total_fetched": 73, "total_relevant": 4, "sentiment_summary": {"positive": 0, "negative": 0, "neutral": 4, "score": 50, "total": 4, "label": "Balanced news tone", "tone": "neutral"}, "classifier": {"primary_event": "general", "primary_label": "Market update", "confidence": 71, "events": [{"event": "general", "label": "Market update", "weight": 1.65, "count": 3}, {"event": "earnings", "label": "Earnings", "weight": 0.55, "count": 1}], "positive_events": 0, "negative_events": 0}, "market_context": {"has_market_context": true, "latest_close": 50.0, "latest_week": "2026-07-10", "one_week_move": 8.7, "four_week_move": 13.6, "twelve_week_move": -23.1, "trend_signal": "0", "trend_label": "Trend inactive", "trend_tone": "negative", "market_dynamics": -1.071066, "market_dynamics_buy_signal": false, "relative_strength": -39.681644, "fair_value_gap": -24.9, "fair_value_label": "Below fair value", "fair_value_tone": "positive", "expectation_direction": "negative", "expectation_probability": 34.7619, "reaction_label": "Price confirming higher", "reaction_tone": "positive", "market_sentence": "+8.7% over one week, +13.6% over four weeks, trend inactive, and below fair value."}, "interpretation": {"label": "Price moving ahead of tone", "tone": "positive", "classification": "price_leads_news", "summary": "Price is moving more forcefully than the current news tone suggests.", "confidence": 55, "badges": ["Value support"], "opportunities": ["Price is below fair value while news tone is not negative."], "risks": [], "event_label": "Market update", "sentiment_word": "balanced"}, "charts": {"sources": [{"label": "TradingView", "count": 2}, {"label": "TipRanks", "count": 1}, {"label": "CRISPR Medicine News", "count": 1}], "tiers": [{"label": "Direct company coverage", "count": 4}, {"label": "Industry context", "count": 0}, {"label": "Sector context", "count": 0}], "events": [{"label": "Market update", "count": 3}, {"label": "Earnings", "count": 1}]}, "insights": [{"label": "Weighted tone", "value": "50/100", "tone": "neutral", "text": "Balanced news tone"}, {"label": "Market reaction", "value": "Price moving ahead of tone", "tone": "positive", "text": "Price is moving more forcefully than the current news tone suggests."}, {"label": "Primary event", "value": "Market update", "tone": "neutral", "text": "71/100 classification confidence."}, {"label": "Company focus", "value": "4", "tone": "positive", "text": "directly relevant articles"}, {"label": "Source quality", "value": "0", "tone": "neutral", "text": "high-authority source matches"}, {"label": "Trend context", "value": "Trend inactive", "tone": "negative", "text": "+8.7% over one week, +13.6% over four weeks, trend inactive, and below fair value."}, {"label": "Latest direct headline", "value": "Neutral", "tone": "neutral", "text": "Enterprise value to revenue forward of BrightPath Biotherapeutics Co.Ltd. \u2013 TSE:4594"}], "updated_at": "2026-07-17T11:22:53.952485+00:00", "disclaimer": "Educational market research only. Not financial, investment, trading, tax, or legal advice."}